<DOC>
	<DOCNO>NCT00442221</DOCNO>
	<brief_summary>The objective study assess safety single-tablet dose Combo Formulation treatment moderate severe migraine</brief_summary>
	<brief_title>The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months</brief_title>
	<detailed_description>The objective study assess safety single-tablet dose Combo Formulation treatment moderate severe migraine , optional second dose least 2 hour follow first dose , need . Combo Formulation administer average least twice per month 12 month .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>1 . Subject male female pregnant lactating . A female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; , Childbearing potential , negative pregnancy test ( urine serum ) screen , employ one follow acceptable measure contraception : Complete abstinence intercourse 2 week prior administration investigational product , throughout study , time interval completion premature discontinuation study account elimination investigational drug ( minimum 24 hr ) ; subject utilizing method must agree use alternate method contraception become sexually active query whether abstinent precede 2 week present clinic randomize treatment ; , Female sterilization ; , Sterilization male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combine progestogen ) ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Any method publish data show low expected failure rate method le 1 % per year . Barrier method use combination acceptable method 2 . Subject 18 – 65 year age . 3 . Subject ’ first migraine occur prior age 50 year . 4 . Subject least 6month history , immediately prior screening , migraine without aura accord International Headache Society criterion ( see Appendix I ) . 5 . Subject experienced average migraine headache frequency 26 moderate severe attack per month previous 6 month . 6 . Subject able distinguish his/her migraine attack discrete type headache . 7 . Subject willing able give write informed consent prior entry study . 1 . Subject receive another investigational drug within 4 week precede study , subject enrol study previously . 2 . Subject concurrent medical psychiatric condition may affect interpretation efficacy and/or safety data otherwise contraindicate participation clinical trial new chemical entity . This include , limited , chronic unstable debilitating disease HIV infection , multiple sclerosis , cancer , etc . 3 . Subject clinically significant disorder , opinion investigator , would result subject ’ inability understand comply requirement study . 4 . Subject history , symptom , sign ischemic cardiac , cerebrovascular peripheral vascular syndrome significant underlying cardiovascular disease . 5 . Subject history cardiac arrhythmia require medication history clinically significant electrocardiogram ( ECG ) abnormality , investigator ’ opinion , contraindicate participation study . 6 . Subject history cerebrovascular abnormality include stroke and/or transient ischemic attack . 7 . Subject , investigator ’ opinion , likely unrecognized cardiovascular disease , base history presence risk factor ( e.g . hypertension , hypercholesterolemia , smoker , obesity , diabetes , strong family history coronary artery disease , female surgical physiological menopause , male 40 year age ) . 8 . Subject evidence history ischemic abdominal syndrome , peripheral vascular disease Raynaud syndrome . 9 . Subject uncontrolled hypertension screening ( sit systolic pressure &gt; 160 millimeter mercury ( mmHg ) , diastolic pressure &gt; 95 mmHg ) . 10 . Subject history epilepsy condition associate lowered seizure threshold . 11 . Subject history basilar hemiplegic migraine . 12 . Subject history impair hepatic renal function , investigator ’ opinion , contraindicate participation study ; subject abnormal laboratory value clinical significance study . 13 . Subject history nonmigraine ( i.e. , tensiontype , sinus , etc . ) headache frequency great equal 15 days/month 3 month prior screen . 14 . Subject &gt; 6 migraine attacks/month either 2 month prior screen . 15 . Subject currently take monoamine oxidase inhibitor ( MAOI ) , take MAOI within 2 week prior screen , plan take MAOI within 2 week treatment . 16 . Subject currently take anticoagulant ( e.g. , warfarin ) NSAID ( except dos aspirin ≤325 mg per day use cardiovascular prophylaxis ) regular basis . 17 . Subject currently take , take previous 3 month , migraine prophylactic medication contain ergotamine , ergot derivative ( dihydroergotamine ) , methysergide . 18 . Subject currently take , take previous 4 week , herbal preparation contain St. John ’ Wort ( Hypericum perforatum ) 19 . Subject hypersensitivity , intolerance , contraindication use sumatriptan naproxen sodium , component , 5HT1 receptor agonist . 20 . Subject history allergic reaction naproxen preparation , include subject aspirin NSAID drug induce syndrome asthma , rhinitis , nasal polyp . 21 . Subject pregnant , actively try become pregnant , breastfeed . 22 . Subject childbearing potential use adequate contraceptive measure . 23 . Subject recent history ( past 3 month ) suggestive alcohol drug abuse dependence , include overuse ( abuse ) ergotamines and/or narcotic treat migraine . Ergotamine abuse daily use 14 consecutive day intermittent consumption exceed 10 mg per week two week . 24 . Subject participate investigational drug trial within previous four week , plan participate another study time period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Migrane headache</keyword>
</DOC>